Imbrave050: Phase 3 Study of Adjuvant Atezolizumab plus Bevacizumab vs Active Surveillance in Patients with Hepatocellular Carcinoma at High Risk of Disease Recurrence after Resection or Ablation

被引：0
|
作者：
Yopp, Adam Charles
Cheng, Ann-Lii
Kaseb, Ahmed Omar
机构：
[1] UT Southwestern Med Ctr, Dallas, TX USA
[2] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[3] MD Anderson, Houston, TX USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS | 2023年 / 237卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [41] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    CANCER RESEARCH, 2021, 81 (13)
  • [42] Preliminary results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection
    Mao, Xianhai
    Duan, Xiaohui
    Wu, Dongde
    Zhou, Cuncai
    Tian, Yifeng
    Shen, Jian
    Xu, Guohui
    Lai, Jianlin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 494 - 494
  • [43] Update results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection
    Mao, X.
    Duan, X.
    Wu, D.
    Zhou, C.
    Tian, Y.
    Shen, J.
    Xu, G.
    Bai, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S658 - S658
  • [44] Adjuvant donafenib for patients with hepatocellular carcinoma at high risk of recurrence following radical resection: A multi-center, retrospective study in China
    Zhang, ShenYu
    Yang, Guibing
    Song, Ruipeng
    Wang, Wei
    Meng, Fanzheng
    Yin, Dalong
    Wang, Jiabei
    Zhang, Shugeng
    Cai, Wei
    Liu, Yao
    Wang, Jizhou
    Luo, Dayong
    Liu, Lianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study
    Kato, Daisuke
    Suzuki, Takanori
    Matsuura, Kentaro
    Okayama, Kohei
    Okumura, Fumihiro
    Nagura, Yoshihito
    Sobue, Satoshi
    Hayashi, Katsumi
    Kusakabe, Atsunori
    Hasegawa, Izumi
    Matoya, Sho
    Mizoshita, Tsutomu
    Kimura, Yoshihide
    Kondo, Hiromu
    Ozasa, Atsushi
    Kawamura, Hayato
    Fujiwara, Kei
    Nojiri, Shunsuke
    Kataoka, Hiromi
    ONCOLOGY, 2024, : 311 - 319
  • [46] Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study
    Wang, Jiabei
    Peng, Tao
    Liu, Chang
    Zhang, Ling
    Zhu, Guangzhi
    Zhang, Xiaogang
    Wang, Xiaoqian
    Liu, Lianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, P.
    Finn, R. S.
    Qin, S.
    Ikeda, M.
    Ducreux, M.
    Kim, T. -Y
    Lim, H. Y.
    Kudo, M.
    Breder, V
    Merle, P.
    Kaseb, A.
    Li, D.
    Verret, W.
    Shao, H.
    Liu, J.
    Li, L.
    Zhu, A. X.
    Cheng, A. -L
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 34 - 34
  • [48] Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence-Free Survival in Hepatocellular Carcinoma Patients With High-Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study
    Shen, Hanchuan
    Liu, Bing
    Zhang, Hangyu
    Liu, Yang
    Li, Chenggang
    MEDCOMM-ONCOLOGY, 2025, 4 (01):
  • [49] Donafenib combined with anti-PD-1 antibody as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: A retrospective analysis
    Li, Chenggang
    Shen, Hanchuan
    Zhang, Hangyu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345